Reasonable Rx Solving the Drug Price Crisis

by Finkelstein, Stan; Temin, Peter

• ISBN13: 9780132344494
• ISBN10: 0132344491
• Edition: 1st
• Format: Hardcover
• Copyright: 2008-01-23
• Publisher: FT Press

Summary

This book differs from the many other books and articles on this topic to take a longer and deeper look at the problem of high drug prices. It reviews the history of drug development, to explain how this window of opportunity was created, describe the industry that transferred new discoveries into drugs that could be swallowed, including how the government has been involved in this process from its inception. Finally, and most importantly, it presents a plan that could keep this window open for all our fellow citizens. The book explores this complicated topic from all angles. It begins by looking at drugs: the different classes of drugs, how they are developed, and how they make money. It then goes on to look at the industry as a whole, examining the forces, both domestically and abroad, that impact and define the industry. This is followed by disastrous past efforts to control drug prices in the form of Medicare part D, as well as a close look at the science of drug development. After explaining in more detail how the drug industry operates, how new drugs are discovered, and how the government affects and controls these processes, the book suggest how to lower drug prices. By examining recent changes in the pharmaceutical industry in more depth, the authors explain how more radical changes can both reduce prices and improve the flow of new drugs.

Author Biography

STAN FINKELSTEIN, M.D., is a Senior Research Scientist at MIT, Co- Director of the MIT Program on the Pharmaceutical Industry (POPI), and serves as a Senior Lecturer on Health Care Policy at Harvard Medical School.

 

PETER TEMIN, Ph.D., a widely cited economist and economic historian, is currently Elisha Gray II Professor of Economics and former head of the Economics Department at MIT. He is the author of Taking Your Medicine: Drug Regulation in the United States.

 

Table of Contents

Acknowledgments	p. viii
About the Authors	p. ix
Introduction	p. xi
Drugs and Drug Prices	p. 1
The American Way to Discover Drugs	p. 21
The Drug Industry Today	p. 39
Are Drug Companies Risky?	p. 59
How Not to Lower Drug Prices	p. 77
Squandering R & D Resources	p. 103
How to Lower Drug Prices	p. 129
Our Solution in Detail	p. 155
Index	p. 177
Table of Contents provided by Ingram. All Rights Reserved.

Excerpts

= 0) {slash = '\\';} else {slash = '/';}openLoc = figLoc.substring(0, figLoc.lastIndexOf(slash) + 1);while (pPage.substring(0,3) == '../') {openLoc = openLoc.substring(0, openLoc.lastIndexOf(slash, openLoc.length - 2)+ 1);pPage = pPage.substring(3, pPage.length + 1);}popUpWin =window.open('','popWin','resizable=1,scrollbars=1,location=0,toolbar=0,width=525,height=394');figDoc = popUpWin.document;zhtm= ' ' + pPage + ' ';zhtm += ' ';zhtm += ' ';zhtm += ' ';zhtm += '' + pPage.substring(pPage.lastIndexOf('/') + 1, pPage.length) + '';zhtm += ' ';figDoc.write(zhtm);figDoc.close();}// modified 3.1.99 RWE v4.1 --> Reasonable Rx INTRODUCTIONThe age of effective medicinal drugs, which dawned about 50 years ago, transformed the health care industry. Americans have become used to taking a pill to cure many diseases and improve their lives in other ways. Many senior citizens, though, can recall growing up in a world where there were no easy cures for many serious conditions that today are regarded as little more than irritations. President Calvin Coolidge's son died from an infection he picked up while playing in the White House rose garden. There's no reason anyone in America should face that risk today. But good drug therapies are only as good as patients' access to them. The best cures in the world are of no use if exorbitant prices put them out of reach.It is no exaggeration to say that we are past being on the verge of a crisis. No one reading this book can honestly deny that the prices of drugs are high and are getting higher. Even for those fortunate enough to have health insurance that pays part of the cost of prescription drugs, the co-payments keep increasing and insurers put more and more restrictions on what therapies they'll cover. As a revolution in science and technology unfolds that brings us new drugs that are targeted almost to the individual patient, the magnitude of the crisis only grows.In the not-too-distant future, perhaps just around the corner, we might be faced with the following scenario: new, more effective, "personalized" drugs that address small patient groups but are priced beyond what any individual can afford and what any insurer is willing to pay. If that happens, then the federal government will intervene to control prices--which the experiences of Europe and Canada have shown kills innovation.What has gotten us to this point? The culprit is a broken system that we've let languish for too long without fixing. It's a flawed system that combines three components that all too often work against each other.The first component ismoney.It costs a fortune to develop a new drug, but the potenti